COMP <GO>
OSUR vs TMCI // 10Y YIELD & FRED MACRO BETA
OraSure Technologies Inc. (NASDAQ) VS. Treace Medical Concepts Inc. (NASDAQ) • 15-METRIC TALLY: OSUR 2
— TMCI 8
■ METRIC PARITY
LAST: $3.46 (-12.31%) • MKT CAP: $271.7M
macro-sensitivity
—
LAST: $4.27 (-3.61%) • MKT CAP: $288.1M
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OSUR VS. TMCI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OSUR | TMCI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.90% | 79.80% | -37.90 | TMCI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -32.40% | -2.60 | TMCI | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -18.91% | -8.96% | -9.95 | TMCI | /fcf-yield <GO> |
| Operating Margin | -60.00% | -25.50% | -34.50 | TMCI | /operating-margins <GO> |
| Net Profit Margin | -59.80% | -27.70% | -32.10 | TMCI | /net-margins <GO> |
| Revenue Growth (YoY) | -38.10% | 1.60% | -39.70 | TMCI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.47 | 0.90 | +1.57 | OSUR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | TMCI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.3 | 50.3 | +1.00 | OSUR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $271.7M | $288.1M | -$16.4M | TMCI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OSUR REV | TMCI REV | OSUR GROSS % | TMCI GROSS % | OSUR FCF | TMCI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $115.0M | $212.7M | 41.9% | 79.8% | -$53.2M | -$29.5M |
| FY 2024 | $185.8M | $209.4M | 42.7% | 80.4% | $23.6M | -$48.8M |
| FY 2023 | $405.5M | $187.1M | — | — | $141.6M | -$34.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OSUR // BETA —
TMCI // BETA —